WVE: Mizuho Maintains Outperform, Raises Price Target to $27 | WVE

NodeGuardian · 2026-03-25T19:05:49+00:00

Mizuho maintains its "Outperform" rating for Wave Life Sciences, raising the price target from $22 to $27, amid analyst upgrades. The consensus target of $35.13 indicates potential growth, despite a lower estimated GF Value from GuruFocus.

NodeGuardian

2026-03-25 19:05:49

Abstract generation in progress

Mizuho has reiterated its “Outperform” rating for Wave Life Sciences (WVE) and increased its price target from $22.00 to $27.00, signaling continued confidence in the stock’s growth potential. This adjustment follows several other analyst upgrades for WVE in early 2026. The average one-year price target from 16 analysts for WVE is $35.13, suggesting a significant upside from its current price, although GuruFocus estimates a lower GF Value.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.